Monday, May 24, 2010 QD Vision buys lighting patents from Motorola
WATERTOWN -- QD Vision Inc., a startup developing nanotechnology-based enhancements for new lighting technologies, said it has bought a patent portfolio from Motorola Inc. Q&A with Laura Lang, chief executive of Digitas
Digitas chief executive Laura Lang talks about social media, career advice, and what she looks for in a job candidate. Constant Contact buys California firm
Constant Contact, a company that provides businesses and nonprofits with e-mail marketing, event marketing, and online survey tools, said it has acquired NutshellMail, a California firm specializing in social media. Hill Holliday's digital practice makes key hires
Boston ad agency Hill Holliday said that Alicia Arnold and Priya Shah have joined its digital practice. FDA grants orphan status to Repligen drug
Repligen Corp. said that the Food and Drug Administration has granted orphan drug designation to RG2833, a company therapy for the treatment of Friedreich's ataxia. Local gas prices fall 4 cents a gallon
The average price of gas in Massachusetts fell 4 cents to $2.829 a gallon in the latest weekly AAA survey, AAA Southern New England said today. Drug is voluntarily withdrawn from UK market
Javelin Pharmaceuticals Inc., a Cambridge developer of acute care pain products, said that a licensee of its Dyloject drug has announced that it is withdrawing all batches of Dyloject from the UK market. Biogen Idec, Abbott move forward on MS drug trial
Biogen Idec and Abbott announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to AVONEX in patients with relapsing-remitting multiple sclerosis. Traber joins Pro-Pharmaceuticals strategy team
Pro-Pharmaceuticals Inc.said that Peter G. Traber, a medical doctor and a member of its board, has been added to the company's regulatory approval strategy and trial design team. NormOxyx raises $17.5 million
NormOxys Inc., a Wellesley biotechnology company, said it has raised $17.5 million in a Series B financing round led by a new investor Care Capital LLC with participation from existing venture investor Index Ventures. Clinical Data gets approval of depression drug
NEWTON -- Federal regulators have accepted an application for a depression drug marketed by Clinical Data Inc., the company said. Today in Globe Business
A sample of Business stories from the print edition of today's Boston Globe | 
No comments:
Post a Comment